small molecule

LAZANDA

FENTANYL CITRATE

Loss of exclusivityJanuary 2032latest FDA-listed patent expiry
CompanyBTCP PHARMA LLC

Drug detail

Brand nameLAZANDA
Active ingredientFENTANYL CITRATE
StrengthEQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalJune 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
9731869January 2032product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LAZANDA patent cliff — loss of exclusivity January 2032 | CliffBio